Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money. But one portion of the pharmaceutical industry is bucking this trend in a major way. Since 2018, licensing deals totaling over US$60 billion have been signed regarding Antibody Drug Conjugates (ADCs), with 2023 alone having at least 18 deals. As a result, worldwide ADC sales are projected to reach US $20-30 billion per year in the near future.
The rapid expansion of ADCs raises many legal and business questions. These questions range from intellectual property rights, FDA/regulatory concerns, and potential litigation issues. In this blog series, we will be addressing these questions and how you can your organization, whether it’s pharmaceutical transactions, regulatory, clinical trial, or litigation concerns, can rely on Foley to assist you with these matters.
